Cantor Fitzgerald Has Weak Forecast for ACRS FY2025 Earnings

Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Equities researchers at Cantor Fitzgerald lowered their FY2025 earnings per share (EPS) estimates for Aclaris Therapeutics in a research report issued on Tuesday, March 18th. Cantor Fitzgerald analyst P. Agrawal now anticipates that the biotechnology company will post earnings per share of ($0.62) for the year, down […]

Leave a Reply

Your email address will not be published.

Previous post Zacks Research Analysts Cut Earnings Estimates for Sunoco
Next post Zacks Research Has Bullish Forecast for AutoZone Q4 Earnings